
US Medical Head, Dyslipidemia
AstraZeneca
Summary
The US Head of Medical – Dyslipidemia is a leadership position that reports directly to the VP Medical Cardiovascular Renal Metabolism (CVRM), within the BioPharmaceuticals Business Unit's US Medical CVRM franchise. The successful candidate will lead a team to develop product and disease area strategies and drive product launches for our novel oral PCSK9 inhibitor across the life-cycle.
Job description
What you'll do:
- Build and lead the dyslipidemia medical team, with accountability for the development and execution of disease area and brand strategies and plans
- Accountable for disease area and brand budget and resource requirements
- Partner effectively with the Commercial Lead, role-modeling effective teamwork across the enterprise
- Effectively act as the US point of contact for the Global Product Team (GPT)
- Provide the US viewpoint into life-cycle management/phase IV strategy and study design
- Develop and maintain positive relationships with key external and internal customers
- Anticipate future trends and needs in the marketplace
- Coach, mentor and performance lead direct reports and take an active role in succession and talent management
- Develop and foster a team culture that encourages continued growth and recognition
- Collaborate and build internal and external networks
- Deliver results in a sophisticated matrix environment, building capabilities, and leading large scale impactful medical initiatives
- Lead the launch of new products
- Leverage AI and digital driven analytics, platforms and clinical solutions to improve medical planning, scientific engagement, evidence generation and patient outcomes
- Ensure compliance with all AZ corporate policies
Requirements for the role:
- Sophisticated Scientific Degree (MBBS, PharmD, PhD, or MD) or equivalent education
- A minimum of 7 years of experience in the pharmaceutical industry, ideally in Medical Affairs and in the dyslipidemia space
- A minimum of 5 years of experience leading high performing teams in the pharmaceutical industry
- Medical/clinical/scientific expertise in CVRM
- US Regulatory Strategy Knowledge/Experience, including new product approval, labeling requirements/negotiations
- Strong business acumen, with comprehensive understanding of the U.S. healthcare environment
Desirable Skills/Experience
- Phase 3b/4 and post-approval dedication research including leading all aspects of patient registries and REMS programs
- Translational medicine, population-based real-world research
- Bridging with coordinated care management & Quality improvement pathways
- Understanding of Health Outcomes Research including Patient-reported outcomes
- Experience integrating emerging technologies—such as AI-supported insights, machine learning tools, or digital medical platforms—into medical affairs strategies or operational processes
Requirements
- Sophisticated Scientific Degree (MBBS, PharmD, PhD, or MD) or equivalent education
- A minimum of 7 years of experience in the pharmaceutical industry, ideally in Medical Affairs and in the dyslipidemia space
- A minimum of 5 years of experience leading high performing teams in the pharmaceutical industry
- Medical/clinical/scientific expertise in CVRM
- US Regulatory Strategy Knowledge/Experience, including new product approval, labeling requirements/negotiations
- Strong business acumen, with comprehensive understanding of the U.S. healthcare environment
Company overview
AstraZeneca is a global, science-led, patient-focused pharmaceutical company dedicated to accelerating the delivery of life-changing medicines that create enduring value for patients, society, and shareholders. With a workforce of over 94,300 employees worldwide, the company operates across three core therapy areas: Oncology, BioPharmaceuticals (including Cardiovascular, Renal & Metabolism, Respiratory & Immunology), and Rare Disease. Headquartered in Cambridge, UK, AstraZeneca maintains strategic R&D centers in Cambridge, Gaithersburg (US), Boston (US), Gothenburg (Sweden), Shanghai, and Beijing. The company generated $54.1 billion in total revenue in 2024 and invested $13.6 billion in scientific research and development. AstraZeneca's bold aspiration is to be pioneers in science, lead in disease areas, and transform patient outcomes, with a goal to launch 20 new medicines and achieve $80 billion in total revenue by 2030. The company is recognized for its commitment to sustainability, health equity, and creating an inclusive work environment where diverse perspectives drive innovation.